This case study scenario examines how the Inflation Reduction Act (IRA) could impede the development of new treatments for diabetes. These treatments are vital in preventing costly complications such as severe kidney function loss and cardiovascular issues. By limiting incentives for continued R&D, the IRA could potentially increase the burden of diabetes-related health problems and associated costs, making it harder to manage this prevalent, chronic condition effectively.
The analysis was commissioned by the Partnership to Fight Chronic Disease (PFCD) and conducted by Lumanity.
